Business Wire

DAIICHI-SANKYO

Share
Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia

Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3 -ITD) positive.

AML is one of the most common forms of leukemia in adults, representing about one-third of all cases.1 In Europe, approximately 18,000 people are diagnosed with AML each year and the five-year survival rate is reported at 17% for adult patients.2,3 Of all newly diagnosed cases of AML, approximately 25% carry the FLT3 -ITD gene mutation, which is associated with a particularly unfavorable prognosis including increased risk of relapse and shorter overall survival.4

“There is a need to improve survival for the majority of patients with acute myeloid leukemia, particularly those with the FLT3 -ITD subtype, which is aggressive and difficult to treat,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “We look forward to working with the EMA to support their review of quizartinib as a potential option for patients with newly diagnosed FLT3 -ITD positive acute myeloid leukemia.”

Validation confirms that the application is complete and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the QuANTUM-First phase 3 trial recently presented at the European Hematology Association (#EHA2022) Congress. In QuANTUM-First, quizartinib combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and continued as monotherapy following consolidation, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) in adult patients with newly diagnosed FLT3 -ITD positive AML compared to chemotherapy alone. The safety of quizartinib combined with intensive chemotherapy and as continuation monotherapy in QuANTUM-First was generally manageable and consistent with previous clinical trials. The incidence of Grade ≥3 QT prolongation was low, with uncommon ventricular arrythmia events. Overall, the risk of QT prolongation was manageable with ECG monitoring, quizartinib dose modification and correction/elimination of additional risk factors.

About QuANTUM-First

QuANTUM-First is a randomized, double-blind, placebo-controlled global phase 3 study evaluating quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, in adult patients aged 18-75 with newly diagnosed FLT3 -ITD positive AML. Patients were randomized 1:1 into two treatment groups to receive quizartinib or placebo combined with anthracycline- and cytarabine-based regimens. Eligible patients, including those who underwent hematopoietic stem cell transplant (HSCT), continued with quizartinib or placebo for up to 36 cycles.

The primary study endpoint was OS. Secondary endpoints include event-free survival (EFS), post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3 -ITD minimal residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints, also were evaluated. QuANTUM-First enrolled 539 patients at 193 study sites across Asia, Europe, North America, Oceania and South America. For more information, visit Clinicaltrialsregister.eu or ClinicalTrials.gov .

About Acute Myeloid Leukemia (AML)

More than 474,500 new cases of leukemia were reported globally in 2020 with more than 311,500 deaths.5 AML is one of the most common types of leukemia in adults, representing about one-third of all cases, and the average age of diagnosis is 68 years old.1 In Europe, approximately 18,000 people are diagnosed with AML each year and the five-year survival rate is reported at 17% for adult patients.2,3 The conventional treatment for newly diagnosed AML is intensive induction and consolidation chemotherapy with HSCT for eligible patients.6,3

About FLT3 -ITD

FLT3 (FMS-like tyrosine kinase 3) is a tyrosine kinase receptor protein normally expressed by hematopoietic stem cells that plays an important role in cell development, promoting cell survival, growth and differentiation through various signaling pathways.4 Mutations of the FLT3 gene, which occur in approximately 30% of AML patients, can drive oncogenic signaling.4 FLT3 -ITD (internal tandem duplication) is the most common type of FLT3 mutation in AML, occurring in about 25% of all newly diagnosed patients, and is associated with increased risk of relapse and shorter overall survival.4

About Quizartinib

Quizartinib is an oral, selective type II FLT3 inhibitor currently in clinical development for treatment of FLT3 -ITD positive AML. In addition to QuANTUM-First, the quizartinib development program includes a phase 1/2 trial in pediatric and young adult patients with relapsed/refractory FLT3 -ITD positive AML in Europe and North America. Several phase 1/2 combination studies with quizartinib are also underway at The University of Texas MD Anderson Cancer Center as part of a strategic research collaboration focused on accelerating development of Daiichi Sankyo pipeline therapies for AML.

Quizartinib, which is currently not approved in Europe, has been granted Orphan Drug Designation for the treatment of AML in Europe, Japan and the U.S. Quizartinib has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with newly diagnosed AML that is FLT3 -ITD positive, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy. Quizartinib is currently approved for use in Japan for the treatment of adult patients with relapsed/refractory FLT3 -ITD AML, as detected by an approved test. Quizartinib is an investigational medicine in all countries outside of Japan.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com .

References

1 American Cancer Society: Key Statistics for Acute Myeloid Leukemia . Updated January 2022.
2 Rodriguez-Abreu D, Bordoni A, Zucca E. Ann Oncol (2007);18 Suppl 1:i3-i8.
3 Heuser M et al. Ann Oncol (2020); 31(6):697 – 712.
4 Daver N et al. Leukemia (2019) 33:299–312.
5 Global Cancer Observatory. Population Fact Sheet: World . Updated March 2021.
6 Daver et al. Blood Cancer J (2020) 10(10):107

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Future According to Barilla: New Sustainability Report Issued9.7.2025 14:00:00 CEST | Press release

Barilla Group has released its latest Sustainability Report, as well as its objectives for 2030, confirming sustainability as a strategic pivot for the future. A commitment that has earned Barilla the recognition, for the second year running, as the leading food company in the world by reputation according to Global RepTrak® 100. “The road will be long and complex as always, but thanks to the commitment and passion of our People we are ready to continue the journey with the same intensity and determination with which we began,” state Guido, Luca and Paolo Barilla. The vision for a more resilient, efficient and future-oriented agriculture involves over 7,000 farmers and 815,000 tons of raw materials purchased according to the specifications of Barilla’s sustainable farming programmes on durum wheat, common wheat, rye, and basil. The Group also supports farmer education through initiatives like Accademia Basilico, offering specialized training to empower farmers and teach techniques for

1GLOBAL and Odido Redefine On-Demand 5G Connectivity With SimWallet9.7.2025 14:00:00 CEST | Press release

1GLOBAL, a technology-driven global mobile communications provider, has partnered with leading Dutch mobile operator Odido to power the launch of SimWallet, a standalone mobile app for eSIM connectivity. SimWallet was introduced into the Dutch market in April this year. It provides near-instant access to Odido’s 5G network in the Netherlands and can be used by anyone, regardless of whether they are an Odido customer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709356448/en/ 1GLOBAL API technology powers the Odido SimWallet Once installed, users can connect to Odido’s state-of-the-art 5G network for unlimited internet for 24 hours, multiple days or up to 30 days, enjoying fixed low rates that work on their smartphone, tablet, laptop or any eSIM-capable device. Rapid integration with intelligent API technology SimWallet utilizes 1GLOBAL’s API technology, which is directly integrated into the Odido network. By utilizing a

Clarity AI Acquires ecolytiq, Further Expanding Its AI Sustainability Solutions to End Consumers9.7.2025 13:00:00 CEST | Press release

The acquisition expands on Clarity AI’s market leading climate engagement offering for global retail and commercial banking financial institutions Clarity AI, one of the world’s largest and most awarded technology and AI firms in sustainability, today announced the acquisition of ecolytiq, a leading provider of in-app climate engagement solutions for financial institutions and their millions of retail and commercial banking customers globally. This strategic move further reinforces Clarity AI’s position at the forefront of the rapidly expanding sustainability tech sector, strengthening its dominance in delivering impactful, data-driven solutions that empower individuals and organizations to make more sustainable choices. With this acquisition, Clarity AI expands its class-leading product portfolio, serving a broad spectrum of market participants—from institutional investors and global corporations to retail banks and individual consumers. The company’s modular, AI-powered platform is d

Valorem Reply Brings AI-powered Image Recognition to Art Basel’s Global Fairs9.7.2025 12:57:00 CEST | Press release

Valorem Reply, part of the Reply Group and focused on delivering innovative digital solutions with Microsoft technologies, partnered with Art Basel – a premier international art fair that hosts shows in Basel, Hong Kong, Miami Beach, Paris and Qatar – to enhance the visitor experience. In partnership with Microsoft, they developed Art Basel Lens, a feature within the Art Basel Companion app that uses image recognition to provide real-time information about artworks directly to visitors’ smartphones, making it easier to explore and engage with the art on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709262853/en/ With Valorem Reply, Art Basel introduced a mobile image recognition feature that connects audiences to artworks using Microsoft Azure. By scanning an artwork, visitors receive structured content about the piece, the artist, and the gallery. The feature supports a more autonomous and fluid exploration of

Venture Global andSEFEAnnounceExpansion of LNG Partnership9.7.2025 12:19:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and Securing Energy for Europe GmbH (SEFE) announced the finalization of an agreement under which SEFE’s subsidiary, SEFE Energy GmbH, will purchase an additional 0.75 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. Today’s announcement amends the existing Sales and Purchase Agreement signed by the companies in 2023, increasing the total volume of LNG purchased by SEFE from CP2 LNG to 3.0 MTPA. Venture Global is expected to become Germany’s largest LNG supplier, with a combined 5 MTPA of 20-year offtake agreements signed with SEFE and EnBW. In addition to its existing long-term agreements, Venture Global to date has supplied Germany with almost 80 cargoes of LNG from its Calcasieu Pass and Plaquemines LNG facilities, enough to power 8 million German homes for one year. “Venture Global is thrilled to expand our strategic partnership with Germany and SEFE and play a leading r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye